Literature DB >> 5944351

Infectious virus-antibody complex in the blood of chronically infected mice.

A L Notkins, S Mahar, C Scheele, J Goffman.   

Abstract

If viremic sera from mice chronically infected with lactic dehydrogenase virus (LDV) were first treated with ether or ultraviolet light to inactivate the infectious virus, neutralizing antibody could be demonstrated. Significant amounts of antibody, however, were not detected until the mice had been infected for about 2(1/2) months and its presence did not result in the elimination of the chronic viremia. Virus isolated from sera containing neutralizing antibody was found to be relatively resistant to neutralization by anti-LDV. Further studies revealed that the resistant virus existed in the form of an infectious virus-antibody complex (sensitized virus). The presence of such a complex was demonstrated by the fact that the virus fraction which persisted after in vivo or in vitro exposure to mouse anti-LDV was readily neutralized by goat anti-mouse sera or goat anti-mouse gamma-globulin, whereas virus that had not been previously exposed to mouse anti-LDV was completely resistant to neutralization by goat anti-mouse sera. These findings suggest that (a) sensitization may play an important role in the resistance and susceptibility of a virus to neutralization by antiviral antibody, and (b) an anti-gamma-globulin may prove useful in neutralizing the resistant fraction and in demonstrating otherwise undetectable antiviral antibody.

Entities:  

Mesh:

Substances:

Year:  1966        PMID: 5944351      PMCID: PMC2138218          DOI: 10.1084/jem.124.1.81

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  17 in total

1.  Studies on the nature of the nature of the neutralization reaction and the competition for neutralizing antibody between components of the virus system of foot-and-mouth disease.

Authors:  C J BRADISH; J O FARLEY; H E FERRIER
Journal:  Virology       Date:  1962-11       Impact factor: 3.616

Review 2.  LACTIC DEHYDROGENASE VIRUS.

Authors:  A L NOTKINS
Journal:  Bacteriol Rev       Date:  1965-06

3.  Kinetic studies on the neutralization reaction between Japanese encephalitis virus and antiserum.

Authors:  N HASHIMOTO; A M PRINCE
Journal:  Virology       Date:  1963-03       Impact factor: 3.616

4.  Studies on the interactions of poliomyelitis virus, antibody, and host cells in tissue culture system.

Authors:  B MANDEL
Journal:  Virology       Date:  1958-10       Impact factor: 3.616

5.  Reversibility of the reaction between polio-virus and neutralizing antibody of rabbit origin.

Authors:  B MANDEL
Journal:  Virology       Date:  1961-07       Impact factor: 3.616

6.  Neutralization of viral infectivity: characterization of the virus-antibody complex, including association, dissociation, and host-cell interaction.

Authors:  B MANDEL
Journal:  Ann N Y Acad Sci       Date:  1960-01-13       Impact factor: 5.691

7.  A study of the basic aspects of neutralization of two animal viruses, western equine encephalitis virus and poliomyelitis virus.

Authors:  R DULBECCO; M VOGT; A G STRICKLAND
Journal:  Virology       Date:  1956-04       Impact factor: 3.616

8.  The development of the phage-inactivating properties of serum during the course of specific immunization of an animal: reversible and irreversible inactivation.

Authors:  N K JERNE; P AVEGNO
Journal:  J Immunol       Date:  1956-03       Impact factor: 5.422

9.  The neutralization of arboviruses. II. Neutralization in heterologous virus-serum mixtures with four group B arboviruses.

Authors:  E G Westaway
Journal:  Virology       Date:  1965-08       Impact factor: 3.616

10.  The neutralization of arboviruses. I. Neutralization homologous virus-serum mixtures with two group B arboviruses.

Authors:  E G Westaway
Journal:  Virology       Date:  1965-08       Impact factor: 3.616

View more
  60 in total

1.  The Anatomy of a Career in Science.

Authors:  Michael B A Oldstone
Journal:  DNA Cell Biol       Date:  2016-02-02       Impact factor: 3.311

2.  Serum Neutralization Anti-IgG Test for Psittacosis.

Authors:  T D Williams; N Hahon
Journal:  Infect Immun       Date:  1970-07       Impact factor: 3.441

3.  Enhanced clearance of lactic dehydrogenase-5 in severe combined immunodeficiency (SCID) mice: effect of lactic dehydrogenase virus on enzyme clearance.

Authors:  T Hayashi; M Ozaki; I Mori; M Saito; T Itoh; H Yamamoto
Journal:  Int J Exp Pathol       Date:  1992-04       Impact factor: 1.925

4.  Enhanced antiglobulin-mediated neutralization of herpes simplex virus-IgG complexes by complement and heterologous anti-immunoglobulin.

Authors:  J C Shivers; C A Daniels
Journal:  Arch Virol       Date:  1979       Impact factor: 2.574

5.  Immunodepression by Rowson-Parr virus in mice. I. Growth curves of Rowson-Parr virus and immunological relationships with Friend virus.

Authors:  M Bendinelli; L Nardini
Journal:  Infect Immun       Date:  1973-02       Impact factor: 3.441

6.  Inhibition of replication of lactic dehydrogenase virus by actinomycin.

Authors:  S Yamazaki; A L Notkins
Journal:  J Virol       Date:  1973-04       Impact factor: 5.103

7.  Effect of a potent interferon inducer on acute and chronic lactic dehydrogenase virus viremia.

Authors:  M L Johnson; H G duBuy
Journal:  Infect Immun       Date:  1975-01       Impact factor: 3.441

8.  Isolation of Clq-binding virus-antibody immune complexes from lactic dehydrogenase virus (LDV)-infected mice.

Authors:  T L McDonald
Journal:  Immunology       Date:  1982-02       Impact factor: 7.397

9.  Antibody classes and subclasses in circulating immune complexes isolated from mice infected with lactic dehydrogenase virus.

Authors:  T L McDonald; T Donnelly; A Weber; L Quenette
Journal:  Immunology       Date:  1983-03       Impact factor: 7.397

10.  Lymphocytic choriomeningitis infection in the nude mouse. An immunopathological study.

Authors:  P Ronco; Y Rivière; Y Thoua; M T Bandu; J C Guillon; P Verroust; L Morel-Maroger
Journal:  Immunology       Date:  1981-08       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.